Georg Kuhnert

2.2k total citations · 1 hit paper
23 papers, 963 citations indexed

About

Georg Kuhnert is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Georg Kuhnert has authored 23 papers receiving a total of 963 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 15 papers in Pulmonary and Respiratory Medicine and 15 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Georg Kuhnert's work include Lymphoma Diagnosis and Treatment (18 papers), Lung Cancer Treatments and Mutations (13 papers) and Medical Imaging Techniques and Applications (12 papers). Georg Kuhnert is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Lung Cancer Treatments and Mutations (13 papers) and Medical Imaging Techniques and Applications (12 papers). Georg Kuhnert collaborates with scholars based in Germany, Netherlands and Switzerland. Georg Kuhnert's co-authors include Markus Dietlein, Carsten Kobe, Alexander Drzezga, Andreas Engert, Peter Borchmann, Bernd Neumaier, Dennis A. Eichenauer, Raphael Richarz, Thomas Fischer and Philipp Krapf and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Georg Kuhnert

19 papers receiving 947 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

2015 286 citations Markus Dietlein, Carsten Kobe et al. Molecular Imaging and Biology profile →

Peers

Georg Kuhnert

RNMI

PRM

ONCOL

PFM

IMMUN

Christof Rottenburger Switzerland

Anna Sutela Finland

Woong‐Ki Chung South Korea

Armin Muigg Austria

Jaleh Fallah United States

Brandon S. Imber United States

Erika J. Lampert United States

Marcel Seiz Germany

Tomáš Kazda Czechia

Robert Nordal Canada

Christof Rottenburger Switzerland

Georg Kuhnert

220 ×0.5

RNMI

242 ×0.6

PRM

354 ×1.0

ONCOL

30 ×0.1

PFM

31 ×0.2

IMMUN

Citations per year, relative to Georg Kuhnert Georg Kuhnert (= 1×) peers Christof Rottenburger

Countries citing papers authored by Georg Kuhnert

Since Specialization

Citations

This map shows the geographic impact of Georg Kuhnert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georg Kuhnert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georg Kuhnert more than expected).

Fields of papers citing papers by Georg Kuhnert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georg Kuhnert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georg Kuhnert. The network helps show where Georg Kuhnert may publish in the future.

Co-authorship network of co-authors of Georg Kuhnert

This figure shows the co-authorship network connecting the top 25 collaborators of Georg Kuhnert. A scholar is included among the top collaborators of Georg Kuhnert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georg Kuhnert. Georg Kuhnert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eich, Hans Theodor, Christian Baues, Michael Fuchs, et al.. (2019). PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 by the GHSG. International Journal of Radiation Oncology*Biology*Physics. 105(1). S1–S1. 3 indexed citations

Mettler, Jasmin, Horst Müller, Conrad‐Amadeus Voltin, et al.. (2018). Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma. Journal of Nuclear Medicine. 60(2). 207–211. 59 indexed citations

Voltin, Conrad‐Amadeus, Jasmin Mettler, Ronald Boellaard, et al.. (2018). Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma. Nuclear Medicine Communications. 40(3). 249–257. 6 indexed citations

Kobe, Carsten, Helen Goergen, Christian Baues, et al.. (2018). Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. Blood. 132(21). 2273–2279. 25 indexed citations

Fuchs, Michael, Helen Goergen, Carsten Kobe, et al.. (2018). PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group. Blood. 132(Supplement 1). 925–925. 12 indexed citations

Eichenauer, Dennis A., Annette Plütschow, Stefanie Kreissl, et al.. (2017). Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. The Lancet Oncology. 18(12). 1680–1687. 70 indexed citations

Dronse, Julian, Klaus Fließbach, Gérard N. Bischof, et al.. (2016). In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease. Journal of Alzheimer s Disease. 55(2). 465–471. 90 indexed citations

Kuhnert, Georg, Heinz Haverkamp, Michael Fuchs, et al.. (2015). Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. Nuklearmedizin - NuclearMedicine. 54(6). 241–246. 3 indexed citations

Dietlein, Markus, Carsten Kobe, Georg Kuhnert, et al.. (2015). Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Molecular Imaging and Biology. 17(4). 575–584. 286 indexed citations breakdown →

10.

Kuhnert, Georg, Ronald Boellaard, Deniz Kahraman, et al.. (2015). Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. European Journal of Nuclear Medicine and Molecular Imaging. 43(2). 249–258. 37 indexed citations

11.

Kříž, Jan, Gabriele Reinartz, Markus Dietlein, et al.. (2015). Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group. International Journal of Radiation Oncology*Biology*Physics. 92(1). 46–53. 16 indexed citations

12.

Kobe, Carsten, Markus Dietlein, Georg Kuhnert, et al.. (2015). The 18F-labeled PSMA_6 compares favorably to 68Ga-labeled PSMA-HBED-CC. A first clinical study in patients with relapsed prostate cancer. 56. 402–402. 1 indexed citations

13.

Rothe, Achim, Stephanie Sasse, Max S. Topp, et al.. (2015). A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 125(26). 4024–4031. 253 indexed citations

14.

Kobe, Carsten, Georg Kuhnert, Deniz Kahraman, et al.. (2014). Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma. Journal of Clinical Oncology. 32(17). 1776–1781. 44 indexed citations

15.

Kahraman, Deniz, Sebastian Theurich, Achim Rothe, et al.. (2013). 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Leukemia & lymphoma. 55(4). 811–816. 17 indexed citations

16.

Dietlein, Markus, Georg Kuhnert, Deniz Kahraman, et al.. (2013). Early Interim PET/CT beim Hodgkin-Lymphom des Erwachsenen - Von der Risikostratifizierung zur Therapiestratifizierung. Der Nuklearmediziner. 36(2). 79–85.

17.

Sasse, Stephanie, Achim Rothe, Helen Goergen, et al.. (2013). Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leukemia & lymphoma. 54(10). 2144–2148. 33 indexed citations

18.

Eich, Hans‐Theodor, Gabriele Reinartz, Carsten Kobe, et al.. (2013). Relapse Analysis After Radiation Therapy of PET-Positive Residual Tumors of Patients With Advanced Stage Hodgkin Lymphoma Treated in the HD15 Trial of the German Hodgkin Study Group (GHSG). International Journal of Radiation Oncology*Biology*Physics. 87(2). S5–S6. 1 indexed citations

19.

Kobe, Carsten, Georg Kuhnert, Deniz Kahraman, et al.. (2013). PET/CT zur Therapiekontrolle beim Hodgkin-Lymphom des Erwachsenen: Hängt die Indikation zur Strahlentherapie vom Ergebnis der PET/CT ab?. Der Nuklearmediziner. 36(2). 86–91.

20.

Mueller, Rolf‐Peter, Horst Mueller, Georg Kuhnert, et al.. (2012). Large mediastinal tumor mass as a prognostic factor in Hodgkin’s lymphoma. Strahlentherapie und Onkologie. 188(11). 1020–1024. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact